Clinical Evidence on Cannabis Use and Trauma-Focused Treatment for PTSD and Substance Use
Clinical Takeaway
Trauma-focused treatments remain effective for PTSD even in patients who use cannabis, including those with co-occurring substance use disorders. Cannabis use at baseline does not appear to undermine the clinical benefits of evidence-based, trauma-focused psychotherapy for PTSD plus SUD populations.
#5 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis clarifies whether trauma-focused treatments maintain efficacy in the substantial subset of PTSD+SUD patients who use cannabis, addressing a critical clinical knowledge gap that currently limits treatment planning confidence. The findings directly inform clinical decision-making about whether to modify, defer, or continue evidence-based PTSD interventions when cannabis use is present alongside other substance use disorders. Understanding treatment outcomes across cannabis use status in this comorbid population has significant implications for individualizing therapy selection and counseling patients about realistic treatment expectations.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
? This meta-analysis addresses a clinically relevant question about whether cannabis use interferes with trauma-focused psychotherapy outcomes in patients with co-occurring PTSD and substance use disorders, drawing from a robust dataset of over 4000 patients across randomized trials. While the aggregated evidence base is substantial, several important caveats deserve attention: the analysis focuses on four specific RCTs within a larger project, cannabis use was likely measured heterogeneously across sites, and the distinction between cannabis use frequency, potency, and abstinence status during treatment may obscure important clinical subtleties. Additionally, the generalizability of RCT participants to real-world clinical populations with more severe comorbidities and polysubstance use patterns remains uncertain. Clinically, this work suggests that evidence-based trauma treatments can still be effective for many patients using cannabis, though providers should carefully assess individual patterns of use, consider targeted harm reduction strategies, and remain attentive to whether active cannabis use is genuinely therapeutic for a patient’s
| |
Have thoughts on this? Share it:
